Cellectar Biosciences Inc [CLRB] stock prices are up 4.65% to $4.05 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CLRB shares have gain 16.38% over the last week, with a monthly amount glided 20.90%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 20, March 2024, Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024. In a post published today on Yahoo Finance, Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:.
From an analyst’s perspective:
On September 13, 2019, ROTH Capital initiated with a Buy rating. Ladenburg Thalmann started tracking the stock assigning a Buy rating and suggested a price target of $2.70 on December 21, 2016.
The stock price of Cellectar Biosciences Inc [CLRB] has been fluctuating between $1.30 and $4.45 over the past year. Cellectar Biosciences Inc [NASDAQ: CLRB] shares were valued at $4.05 at the most recent close of the market.
Analyzing the CLRB fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.75, Equity is -16.68 and Total Capital is -6.66. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.86 points at the first support level, and at 3.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.19, and for the 2nd resistance point, it is at 4.32.
Cellectar Biosciences Inc [CLRB] reported earnings per share of -$1.28 for its fiscal quarter that ended on 9/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.21/share, meaning a difference of $-0.07 and a surprise factor of -5.80%. By comparison, the stated earnings for the previous quarter ended on 6/29/2022 were -$1.22 per share as compared to estimates of -$1.03 per share, a difference of $-0.19 representing a surprise of -18.40%.
Ratios To Look Out For
It’s worth pointing out that Cellectar Biosciences Inc [NASDAQ:CLRB]’s Current Ratio is 1.22. Also, the Quick Ratio is 1.22, while the Cash Ratio stands at 1.15.
